MARKSANS PHARMA LTD.
Cah Flow
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
---|---|---|---|---|---|
Profit Before Tax | 3376.53 | 2475.11 | 3021.64 | 1571.72 | 1043.07 |
Adjustment | 742.38 | 353.07 | 565.66 | 420.38 | 318.84 |
Changes In working Capital | -1114.65 | -1107.02 | -1316.10 | 591.17 | -817.92 |
Cash Flow after changes in Working Capital | 3004.26 | 1721.16 | 2271.20 | 2583.27 | 543.99 |
Cash Flow from Operating Activities | 2374.12 | 992.57 | 1785.90 | 2333.27 | 273.95 |
Cash Flow from Investing Activities | -2592.12 | -843.91 | -448.49 | -595.84 | -134.80 |
Cash Flow from Financing Activities | 1978.29 | 795.11 | -152.85 | -1135.54 | -207.77 |
Net Cash Inflow / Outflow | 1760.29 | 943.77 | 1184.56 | 601.89 | -68.62 |
Opening Cash & Cash Equivalents | 2064.06 | 1120.29 | 937.27 | 335.38 | 397.17 |
Cash & Cash Equivalent on Amalgamation / Take over / Merger | NA | NA | NA | NA | NA |
Cash & Cash Equivalent of Subsidiaries under liquidations | NA | NA | NA | NA | NA |
Translation adjustment on reserves / op cash balalces frgn subsidiaries | NA | NA | NA | NA | NA |
Effect of Foreign Exchange Fluctuations | 0.02 | NA | NA | NA | NA |
Closing Cash & Cash Equivalent | 3824.37 | 2064.06 | 2121.83 | 937.27 | 328.55 |